Rock Springs Capital Management LP Akero Therapeutics, Inc. Transaction History

Rock Springs Capital Management LP

$2.94 Billion
Q3 2024

A detailed history of Rock Springs Capital Management LP transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Rock Springs Capital Management LP holds 933,399 shares of AKRO stock, worth $27.4 Million. This represents 0.91% of its overall portfolio holdings.

Number of Shares

933,399

Previous 1,074,261 13.11%

Holding current value

$27.4 Million

Previous $25.2 Million 6.26%

% of portfolio

0.91%

Previous 0.78%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$21.45 - $29.34 $3.02 Million - $4.13 Million	-140,862 Reduced 13.11%	933,399 $26.8 Million
Q2 2024 Aug 14, 2024	SELL	$18.31 - $24.62 $4.13 Million - $5.55 Million	-225,627 Reduced 17.36%	1,074,261 $25.2 Million
Q1 2024 May 15, 2024	BUY	$17.76 - $31.18 $3.89 Million - $6.82 Million	218,824 Added 20.24%	1,299,888 $32.8 Million
Q4 2023 Feb 14, 2024	SELL	$11.38 - $50.33 $3.85 Million - $17 Million	-338,086 Reduced 23.82%	1,081,064 $25.2 Million
Q3 2023 Nov 14, 2023	SELL	$41.19 - $52.25 $5.42 Million - $6.88 Million	-131,604 Reduced 8.49%	1,419,150 $71.8 Million
Q2 2023 Aug 14, 2023	BUY	$36.89 - $56.88 $3.56 Million - $5.49 Million	96,500 Added 6.64%	1,550,754 $72.4 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $50.24 $2 Million - $2.69 Million	53,600 Added 3.83%	1,454,254 $55.6 Million
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $1.03 Million - $1.68 Million	30,681 Added 2.24%	1,400,654 $76.8 Million
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $7.01 Million - $23.5 Million	690,459 Added 101.61%	1,369,973 $46.6 Million
Q2 2022 Aug 15, 2022	BUY	$8.0 - $15.01 $354,400 - $664,943	44,300 Added 6.97%	679,514 $6.42 Million
Q1 2022 May 16, 2022	BUY	$12.97 - $22.26 $624,025 - $1.07 Million	48,113 Added 8.2%	635,214 $9.01 Million
Q4 2021 Feb 14, 2022	BUY	$19.87 - $26.24 $365,608 - $482,816	18,400 Added 3.24%	587,101 $12.4 Million
Q3 2021 Nov 15, 2021	BUY	$18.65 - $25.46 $747,865 - $1.02 Million	40,100 Added 7.59%	568,701 $12.7 Million
Q2 2021 Aug 16, 2021	BUY	$24.81 - $32.35 $184,338 - $240,360	7,430 Added 1.43%	528,601 $13.1 Million
Q1 2021 May 17, 2021	BUY	$24.04 - $34.19 $139,432 - $198,302	5,800 Added 1.13%	521,171 $15.1 Million
Q4 2020 Feb 16, 2021	BUY	$25.12 - $29.89 $2.32 Million - $2.76 Million	92,331 Added 21.83%	515,371 $13.3 Million
Q3 2020 Nov 16, 2020	BUY	$30.79 - $39.92 $5.54 Million - $7.19 Million	180,055 Added 74.1%	423,040 $13 Million
Q2 2020 Aug 14, 2020	BUY	$19.25 - $26.76 $346,211 - $481,278	17,985 Added 7.99%	242,985 $6.06 Million
Q2 2019 Aug 14, 2019	BUY	$18.08 - $19.83 $4.07 Million - $4.46 Million	225,000 New	225,000 $4.31 Million

Others Institutions Holding AKRO

# of Institutions

190

Shares Held

73.8M

Call Options Held

241K

Put Options Held

647K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.36B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Springs Capital Management LP with notifications on news.

Account

Rock Springs Capital Management LP Akero Therapeutics, Inc. Transaction History